Prurigo Nodularis Treatment Market to expand at a steady CAGR of 4.8% by 2028

According to the latest report published by Future Market Insights titled ‘Prurigo Nodularis Treatment Market: Global Industry Analysis 2013 – 2017 and Opportunity Assessment 2018 – 2028’, the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018–2028. The global market for prurigo nodularis treatment is expected to reach a valuation of US$ 697.9 Mn by 2028 end, attesting the highest growth rate by Middle East & Africa, which is expected to expand at 4.8% CAGR over 2018–2028.

Global Prurigo Nodularis Treatment Market: Factors Influencing Growth

Favourable regulations and initiatives for orphan drug development in various regions is expected to fuel the market for prurigo nodularis treatment in the near future. The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global prurigo nodularis treatment market.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-3339

Global Prurigo Nodularis Treatment Market: Segmental Insights

The global prurigo nodularis treatment market has been segmented on the basis of product type, distribution channel and region. Prurigo nodularis treatment product types include corticosteroids, emollients, capsacin cream, antihistamines and others.  Globally, capsacin cream under the product type segment stands the most attractive product form amongst the different product types. Among all distribution channels of prurigo nodularis treatment, retail pharmacies are anticipated to be the most lucrative distribution channel followed by hospital pharmacies.

Global Prurigo Nodularis Treatment Market: Regional Highlights

With nearly 40% - 45% market share, Western Europe dominated the global prurigo nodularis treatment Market in 2017, partly due to the presence of leading market players and key research and development initiatives taken by governments in the region. Moreover, in developing regions such as Latin America, advanced medical facilities are helping the region cope with the current healthcare crisis. North America is the second largest regional market for prurigo nodularis treatment and is expected to be valued at US$ 75.6 Mn by 2028, with the markets in U.S.A and Canada growing at a faster rate. Eastern Europe is projected to be the third largest market for prurigo nodularis treatment.

Key Research Findings

• The global prurigo nodularis treatment market is expected to create incremental opportunity of US$ 197.9 Mn between 2018 and 2028
• The prurigo nodularis treatment market is expected to witness fast and steady growth, partly due to the rising government support across various regions and increasing demand for prurigo nodularis treatment across the world.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-3339

Global Prurigo Nodularis Treatment Market: Vendor Insights

The global market for prurigo nodularis treatment is highly competitive with many players operating in the global market. Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others. In order to increase market coverage, companies are focussing on building close collaborations with local distributers as these partnerships allow firms to grow and expand in the global market.

Membrane Microfiltration Market to Cross US$ 8 Bn by 2028

Several traditional techniques such as pasteurisation, heat treatment, and sterilisation have long been used to improve the shelf life of milk. One of the newest alternatives to heat treatment is microfiltration that reduces bacteria and improves the shelf life of dairy products, while also preserving the basic taste. Adoption of membrane microfiltration in milk is one of the trends being witnessed in the global market, according to a new research study on the global membrane microfiltration market by Future Market Insights. An increasing adoption of ceramic microfiltration membranes for cross flow filtration in water plants is another key trend, as ceramic membranes help maintain a high filtration rate and ensure enhanced savings in membrane replacement costs.

Manufacturers in the membrane microfiltration market are producing robust microfiltration systems using large filter cartridges that occupy lesser space and eliminate the number of filtration system connections, thereby reducing maintenance costs. A preference for continuous fermentation over batch processing is also being observed, with manufacturers increasingly deploying membrane microfiltration technology in their plants. These trends are likely to positively impact revenue growth of the global membrane microfiltration market in the coming years. According to Future Market Insights forecasts, sales revenue in the membrane microfiltration market is anticipated to cross US$ 8 Bn by 2028, from an estimated value of about US$ 3.8 Bn in 2018. A decadal growth rate of 7.8% can be attributed to several factors, of which Future Market Insights throws deeper insights in this research study.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-5402

Increasing Applications in Industrial Biotechnology and Widespread Use of Large Molecule Biopharmaceuticals Pushing Revenue Growth of the Global Membrane Microfiltration Market
Membrane microfiltration is finding application in the production of biofuel and bio refineries are incorporating this technology to lower the overall energy costs and reduce industrial bio waste. Membrane microfiltration is also increasingly used in biodiesel processes where this technology is used to reuse water especially in areas of water scarcity. The rising industrial applications of membrane microfiltration are fuelling revenue growth in the global market. Also, filtration is a critical component of biopharmaceuticals production, and membrane microfiltration is widely used to remove cellular debris and other cellular colloids. With a growing adoption of large molecule biopharmaceuticals owing to their therapeutic properties, the demand for membrane microfiltration technology in the production of biopharmaceuticals is expected to surge in the near future.

Membrane microfiltration is also extensively used in the food and beverages industry as a technology to separate and purify components and improve the quality and yield of food products. An increasing use in vegetable and fruit juices, fermented dairy products, milk and dairy products, non-alcoholic beverages, and other food and beverage products is expected to spur revenue growth of the global membrane microfiltration market to a significant extent. One of the other critical application areas of membrane microfiltration is in water treatment plants. Membrane microfiltration helps remove unwanted particles from water before the water is treated for purity using other processes such as reverse osmosis. A growing need for quality potable water is further driving growth of the membrane microfiltration market.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-5402

Future Market Insights Recommends…

With newer applications of membrane microfiltration coming to the fore, Future Market Insights feels there is a great deal of opportunity for key players operating in the global market. Water treatment and food and beverages are two important end-use application areas that manufacturers can target with their advanced solution offerings. China is projected to be the fastest growing regional market for membrane microfiltration in terms of demand for the technology, and manufacturers would be well advised to focus on this region to augment their market share. By setting up robust supply chains in regions that are anticipated to develop at a faster pace in the coming years, manufacturers can benefit from the lucrative opportunities presented by local markets to up their current standing in the global membrane microfiltration market.

Will Implantable Bioartificial Kidneys Eradicate the Need for Dialysis in Patients with Renal Failure?

Patients with end-stage renal disease (ESRD) currently have two treatment options – kidney transplant and dialysis. The limited number of kidney donors worldwide and the various medical complications that arise from dialysis have pushed the medical fraternity to look for suitable alternatives to treat ESRD. Implantable bio artificial kidneys are the latest innovation in healthcare science that provide the health benefits of kidney transplantation and potentially wipe out the need for dialysis. Powered by silicon nanotechnology, artificial kidneys seek to eliminate the torture faced by dialysis patients and may prove to be a boon to patients with acute renal failure.

In a new development, the Kidney Research Institute of the University of Washington is currently developing a wearable artificial kidney that is expected to go into clinical trials in 2022. This could be a game changer in the medical devices sector, and may reduce the dependency on dialysis equipment to a great extent.
To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-711

Dialysis Continues to Remain Dominant Therapy to Treat ESRD

While developments in the global healthcare sector continue to focus on innovative products and therapies, dialysis is currently the most administered treatment option for ESRD. Dialysis equipment is in great demand in hospitals, clinics, and dialysis centres across the world, boosting demand in the global market. According to a recent research study published by Future Market Insights, the global dialysis equipment market is projected to register a CAGR of 4.8% and will likely reach a valuation of US$ 23.6 Bn by 2028 end. The medical sector meanwhile continues to introduce newer dialysis equipment in the global market to address the varied needs of patients.

Portable Home Dialysis Equipment Trending the Global Market

Home dialysis has remained a preferred option for patients with renal disease as it is more convenient and less expensive than hospital based dialysis. Leading medical devices manufacturer Quanta has recently launched advanced haemodialysis equipment with an objective to improve the lives of patients requiring dialysis on a regular basis. This is an extremely flexible dialysis treatment that patients can take in the comfort of their homes. Quanta’s home dialysis equipment is portable, lightweight, and very easy to use. This dialysis equipment also incorporates advanced technology such as high-res screens with touchscreen functionalities and helps enhance patient outcomes.

Manufacturers of dialysis equipment are developing fully automatic, portable, and advanced dialysis equipment to treat patients of all ages suffering from ESRD. A notable technological advancement includes the introduction of high-efficiency and high-flux membranes, enabled by technical advances in membrane technology and polymer chemistry. Unlike traditional renal replacement machines, automated dialysis equipment facilitates the management of disease parameters digitally, thereby ensuring more accuracy and reducing costs of labour.

Wearable Dialysis Equipment to Ease Patient Discomfort; Expected to Rule the Global Market

With technology having proliferated every aspect of human lives, the innovation of wearable dialysis equipment is a blessing for countless dialysis patients, who can now break the shackles of confinement to fixed dialysis equipment and enjoy increased mobility. Wearable dialysis equipment is a miniature artificial HD machine based on dialysate regenerating sorbent technology. Designed for use as a belt, patients can wear this dialysis equipment for slow, gentle dialysis. This dialysis equipment is touted to best mimic the natural kidney function of blood cleansing. Given the continuous advancements taking place in medical device technology, wearable dialysis equipment may soon emerge in a more compact and small form factor to provide increased convenience and usability to patients.

Miniature artificial kidneys could redefine the entire ecosystem of dialysis treatment. The integration of portable home haemodialysis equipment facilitating elongated use in homes and offices with wearable artificial kidneys for peritoneal dialysis allowing uninterrupted blood cleansing throughout the day will ensure more patient comfort and guarantee better and enhanced performance of the dialysis equipment.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-711

The dialysis equipment market is expected to witness significant innovations in the coming years. Whether an upgrade to existing dialysis equipment or a viable alternative to dialysis itself, new-age dialysis equipment will promise increased mobility, less trauma, more peace of mind, and reduction in the burden of healthcare costs. 

Event Management Software Market to expand at a steady CAGR of 12.1% by 2026

Companies have begun the usage of event management software as it helps in improving the efficiency of the events business. The significant features of this software helps in powering successful events for industries as well as organizations of all sizes.

Global Market for Event Management Software: Dynamics Influencing Revenue Growth

With regards to revenue, the software segment is the most significant segment in the global event management software market and is projected to attain a market value of greater than US$ 5,000 Mn in 2017. Apart from this, software segment is expected to display substantial revenue growth owing to the increase in the adoption of professional services by corporate companies. The improved benefits of event management software is the key factor enhancing the adoption as well as growth of the software segment over the predictable period.

Social media platforms are turning out to be the most popular way for promoting as well as marketing events, social causes, campaigns, etc. The registration process is supported by software segment and people who visit the particular page on Facebook will be provided with e-ticket on their smartphone by the event management software. The e-ticket just has to be shown in the venue and entry will be given soon after the formalities of payment is done, which is either through cash or online payment. The ease and convenience of this process is also an important factor that eventually drives the market. Additionally, increase in the adoption of cloud-based solutions due to ease in accessibility and cost-efficiency is also aiding to the growth of software segment. All of these factors together are producing robust development in the global market for event management software’s software segment.

Request for sample copy of report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-1849 

Taxonomy of Global Market for Event Management Software

The segmentation of the global market for event management software is done on the basis of enterprise type, deployment type, component type, industry type as well as region.

On the basis of enterprise type, the global market for event management software is segmented into large, medium and small enterprise. On the basis of deployment type, the global market for event management software is segmented into cloud and on-premise. Depending on the component type, the global market for event management software is segmented into software and services. Based on the sub-segment, software is segmented further into analytics and reporting, venue management, event marketing, event planning and others. Based on the sub-segment, services is segmented further as managed services and professional services. On the basis of industry type, the global market for event management software is segmented into travel and hospitality, education, government, event planner, corporate and others. On the basis of region, the global market for event management software is segmented into MEA, Japan, APEJ, Eastern Europe, Western Europe, Latin America and North America.

Regional Analysis

The market for event management software in North America is expecting that revenue from its software segment to upsurge at a reasonably high CAGR throughout the forecast period. Also, in this segment, the sub-segment namely event planning, is projected to upsurge at a high revenue CAGR throughout the forecast period. In Latin America, the sub-segment namely professional services is expected to expand at a high revenue CAGR throughout the projected period. In APEJ region, due to increase in the adoption of event marketing and venue management solutions, the software segment’s revenue is anticipated to upsurge at a high CAGR. The market for event management software in MEA is expecting that revenue from its software segment to upsurge at a reasonably high CAGR. This expectation is based on increase in the adoption of software for online event organizing, online registration, event planning and others.

Request to view Table of Content @: https://www.futuremarketinsights.com/askus/rep-gb-1849

Competition Landscape of Global Market for Event Management Software

The extensive research report on the global market for event management software covers analysis on the major companies active in the global market for event management software. Key companies such as SocialTables, EventZilla, Gather Technologies Inc., Certain, Inc., Zerista, Ungerboeck Software International, Bizzabo Inc., EventBrite Inc., etouches Inc., Zoho Corporation, Cvent, Inc., and Xing Events are profiled in this research report.

Diabetes segment market revenue share projected to grow at a significant CAGR owing to increasing prevalence of diabetes in Asia Pacific and MEA regions

Differential and innovative product strategies that are adopted by various multinational pharma companies have been fuelling the growth of branded generics market at a global scale. These strategies include establishing sustained local capabilities with the strong local talents, engaging in portfolio marketing, recalibrating regulatory affairs, bolstering sales force with the multi-channel engagement and enhancing contracting capabilities. Developing regions are witnessing a rapid increase in demand for branded generics on account of increasing affordability of the products and ease of regulations. Rising disposable income and changing lifestyle of consumers is also expected to augur well for growth of the branded generics market in the near future.

The study predicts that patent expiries of the blockbuster drugs are likely to create demand for branded generics during the forecast period. Increasing prevalence of the lifestyle and chronic diseases such as cardiovascular diseases and diabetes together with increasing purchasing power makes branded generics market attractive for investors. The study by Future Market Insights predicts that branded generics market is likely to register a healthy 7.3% CAGR over the forecast period, 2016-2026. Commodity generic products and huge competition from the branded drugs have prevailed as major challenges inhibiting the growth of branded generics market, in terms of price structure.

Request for sample copy of report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-1260 

Cardiovascular Diseases are likely to prove highly lucrative for revenue growth of branded generics market due to rising prevalence of diverse types of cancers and increasing comorbidities across the globe. Anti-hypertensive segment is expected to prove highly lucrative for the purpose of reducing premature cardiovascular disease. Oral formulations hold the largest demand from medical providers and patients for branded generics. This is mainly due to the benefits that oral formulation offers such as accuracy, dosing convenience and easy adherence to a medication plan.

Parenteral formulations are likely to gain traction in branded generics market during the forecast period, with API (active pharmaceutical ingredient) being degraded in intestinal tracts, thereby driving the demand for parenteral delivery. The report predicts that APEJ and North America are likely to remain lucrative for parenteral formulations during the forecast period. Retail Pharmacies are expected to prove as the most lucrative distribution channel for branded generics, as the pharmaceutical companies’ manufacturers are highly dependent on this distribution channel for selling the products over-the-counter.

APEJ accounts for the largest revenue share in the branded generics market owing to lack of worldwide health coverage and higher out-of-the-pocket expenditure on healthcare. China, India and ASEAN countries are expected to pose lucrative growth opportunities for the new and existing key players in the forthcoming years. Most of the leading manufacturers in the global market are concentrated in Asian countries and have been working towards expansion of their production capacity, for catering to the existing and emerging global demands.

Statutory regulatory bodies have been playing a significant role in the growth branded generics market in APEJ by providing approvals for products. Furthermore, growth through the adoption of inorganic approaches have been forming cornerstone of the branded generics drug makers in APEJ region. Latin America, Eastern Europe and North America will prove significantly lucrative for the branded generics market in the forthcoming years.

Request to view Table of Content @: https://www.futuremarketinsights.com/askus/rep-gb-1260

Brand-name prescriptions are anticipated to remain ubiquitous amongst the aged people worldwide. Since geriatric demographics hold a larger portion of drug-consuming population across the globe, demand for branded generics are expected to rise substantially. Branded generics market has been projected to develop at a healthy pace as enormous number of the pharmaceutical products are expected to go off-patent within the assessment period of 2016-2026.

Pharmaceutical Filtration Market Would Reach US$ 17 billion by 2022

Active pharmaceutical ingredients are a key component of the pharmaceutical industry in the 21^st century. Filters are essential in a number of cases during the course of API creation and are necessary in bioscience laboratory applications as well. An increased production of large biologics and molecules, nano fibre technological advancements, generic market growth, and regulatory guidelines for cleanroom pharmaceutical production are the main factors driving the pharmaceutical filtration market. Additional funds diverted towards R&D expenditure by major biopharmaceutical organizations also boost the profile of the pharmaceutical filtration market. According to Future Market Insights, the pharmaceutical filtration market is expected to record a robust CAGR of 6.1% for the period from 2017 to 2022.

• Manufacturing has the major portion of the revenue share in the pharmaceutical filtration market by operation in 2017 and is likely to remain so throughout the duration of the forecast period. The manufacturing segment is expected to cross a value of more than US$ 9.3 billion by end 2022 making it imperative for companies to be present in this operation segment of the pharmaceutical filtration market. The pilot scale segment follows at a considerable distance but cannot be overlooked entirely in favour of manufacturing. The pilot scale filtration segment has strong scope in North America as the continent represents a little over a third of the pharmaceutical filtration market and is estimated to retain this share going forward
  

Request for sample copy of report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-5028

• The cell separation segment comprises slightly above a sixth of the pharmaceutical filtration market by application and is predicted to lose popularity in the future. Nonetheless, the North America cell separation market alone is on track to push past a billion dollars by end 2022 and companies are advised to take this into account while devising their business strategies. The water purification segment has a similar revenue share to the cell separation segment in the pharmaceutical filtration market by application. After North America, the water purification segment is particularly prominent in Europe
  
• In terms of technology, microfiltration is quite popular as it contributes nearly half the revenue share in the pharmaceutical filtration market in the year 2017. Furthermore, microfiltration is anticipated to witness a high CAGR of more than 5.5% for the period 2017-2022 ensuring that all key stakeholders have ample opportunity in this lucrative technology. Ultrafiltration is not as prominent as microfiltration in the pharmaceutical filtration market but is gaining traction recently. Ultrafiltration technology has the greatest scope in both North America and Europe as these two continents are projected to cross a billion dollars in terms of value by end 2022
  
• North America is the largest region in the pharmaceutical filtration market and is poised to grow to more than US$ 6 billion by end 2022
  

Request to view Table of Content @: https://www.futuremarketinsights.com/askus/rep-gb-5028

• The report has profiled a few of the companies in the pharmaceutical filtration market. These include The Marmon Group LLC, Sartorius Stedim Biotech, Meissner Filtration Products, Parker Hannifin Corporation, Pall Corporation, Merck KGaA, GE Healthcare Inc., Eaton Corporation Plc., Amazon Filters Ltd., and 3M Companies.
  

Empty Capsules Market: Increased demand for vegetarian empty capsules in developing markets to create significant revenue traction

Steady increase in the number of photochemically unstable drugs will continue to positively influence the growth of the empty capsules market in 2016, with global revenues expected to increase by 6% to reach US$ 1,432.6 Mn. 

Increasing demand for vegan and Halal pharmaceuticals is ramping up adoption, and providing support to a market, which is primarily driven by Type-A (pork-based) capsules. Development of hypromellose capsules for the treatment of pulmonary and non-pulmonary diseases are also creating growth opportunities for manufacturers.

Gelatin-based capsules will continue to account for higher demand than vegetarian-based capsules, accounting for nearly 71% revenue share of the market in 2016.  Type-A (pork skin), the largest segment in terms of raw materials, will grow at a lower rate than non-pork based empty capsules, especially hydroxy propyl methyl cellulose (HPMC) and fish bone gelatin. While type-A (pork skin) revenues will grow by 4.62% in 2016, fish bone gelatin and HPMC revenues will grow by 8.87% and 8.40% respectively.

A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-782  

Size “4” capsules will continue to be the largest revenue segment on the basis of capsule size, with total revenues expected to reach US$ 263.1 Mn in 2016. Size “1” and Size “2” capsules will also account for substantial demand, collectively accounting for over US$ 430 Mn in market revenues in 2016.

Empty capsules are administered orally, and only a small percentage of these drugs is inhaled – the former accounted for 91.1% revenue share of the global market in 2015. While inhalation-based empty capsules will grow at a higher rate, they will continue to account for a revenue share of less than 10% of the overall market.

Pharmaceutical companies – the largest end-use segment for empty capsules – will continue to post strong gains in 2016. Revenues from this segment are anticipated to increase at 5.79% in 2016 to total US$ 940.8 Mn. Demand will also be healthy in the cosmetics and nutraceutical sector, with this segment collectively accounting for nearly US$ 360 Mn in revenues in 2016.

The U.S. is the largest market for empty capsules, with total revenues expected to reach US$ 500 Mn in 2016. The North America empty capsules market (U.S. and Canada) is the largest globally in terms of revenues, accounting for nearly 43% revenue share of the market. Western Europe will maintain its position as the second largest market for empty capsules, with total revenues expected to reach US$ 279.4 Mn in 2016. Germany and France are the two largest markets in terms of revenues, with the former accounting for the highest revenue share and the latter growing at the highest rate.

Key players in the global empty capsules market included include Capsugel, ACG Worldwide, CapsCanada Corporation, Roxlor LLC, Qualicaps, Inc., Suheung Co., Ltd., Medi-Caps Ltd., Sunil Healthcare Ltd., Snail Pharma Industry Co., Ltd. and Bright Pharma Caps, Inc.

To view TOC of this report is available upon request @ https://www.futuremarketinsights.com/askus/rep-gb-782

Long-term Outlook: The global empty capsules market is anticipated to increase at a CAGR of over 7% to reach US$ 2,902.5 Mn in revenues by 2026.

Digital Pathology Market: Increasing Adoption in Cancer Research and Diagnosis to boost the market for Digital Pathology Scanning

Future Market Insights (FMI) recently announced the release of its report titled “Digital Pathology Market: Global Industry Analysis and Opportunity Assessment, 2015 - 2025.” According to the report, the global digital pathology market, estimated to be valued at US$ 326.7 Mn in 2015-end, is expected to expand at over 11% CAGR to total US$ 954.4 Mn by 2025.

According to FMI’s report, growing need for real-time access to pathology outcomes is a key factor fuelling widespread adoption of digital pathology services. Increasing initiatives by pharmaceutical companies to develop novel medicines for cancer treatment has also contributed to increase the scope of digital pathology systems.

Adoption of digital pathology services and solutions is anticipated to witness robust growth in the regions of North America and Western Europe, owing to favourable regulations and affordability. Although the use of digital pathology in primary diagnosis is restricted in the U.S., robust adoption across research centres has provided an impetus to the market in the country.

A sample of this report is available upon request @  https://www.futuremarketinsights.com/reports/sample/rep-gb-124

According to FMI’s report, Asian countries are facing challenges in adopting digital pathology solutions owing to high cost structure, complexity in practical implementation of cloud-based digital pathology systems, and a general lack of awareness about digital pathology systems.

FMI’s report has segmented the digital pathology market on the basis of components, screening services, and end-users. The report also offers region-wise forecast and analysis on the key companies operating in the digital pathology landscape.

On the basis of components, the digital pathology market is broadly segmented into hardware, software and services.

The hardware segment includes scanner and other platform technologies, which currently accounts for major share of the global market. The software segment comprises on-premises software and cloud-based software. The on-premises software solution sub-segment has been estimated to account for largest share in the overall digital pathology software market in 2015.

On the basis of screening services, the histopathology screening segment has been estimated to account for 81% share of the overall digital pathology market in 2015. This is attributed to increasing usage of digital pathology systems in cancer research for histopathology screening of test samples.

On the basis on end user, the research centre segment is estimated to remain dominant in the global digital pathology market over the forecast period, owing to higher adoption among drug discovery and development industry, which includes, research centres, contract research organisation and others. This segment has been estimated to account for 63% share of the overall digital pathology market revenue in 2015.

Key trends identified in the digital pathology market include use of digital pathology as second-opinion collaboration technology in cancer treatment, increasing research activities in personalized medicines, and integration of LIS, LIMS and EMR solution with digital pathology.

Implementation of image lifecycle management, disaster recovery solutions, tiered storage management plans in data management in on-premises as well as cloud-based solution are driving the adoption of digital pathology in the healthcare sector globally.

Leading Companies in Digital Pathology Market

Key market players covered in the report include Perkin Elmer, Inc., MedImmune, LLC (AstraZeneca), Sectra AB, Koninklijke Philips N.V, GE Healthcare, Inspirata Co., Ventana Medical Systems, Inc., Leica Biosystems, 3D-Histech Ltd, Hamamatsu Photonics, K.K., Digipath Co., ZEISS, Olympus Corporation, and Yokogawa Electronic Corporation.

To view TOC of this report is available upon request @ https://www.futuremarketinsights.com/askus/rep-gb-124

These leading players are bolstering their position through product launches and acquisitions as a key development strategy in order to sustain their position in the competitive market. The Tier 1 companies are focusing on a collaborative approach with cloud service providers to provide overall service to end-users.

Contrast Media Injectors Market to expand at a CAGR of 5.6% by 2025

Future Market Insights (FMI), in its latest report titled ‘Contrast Media Injectors Market: Global Industry Assessment and Forecast, 2015-2025’, has projected the global contrast media injectors market revenue to expand at a CAGR of 5.6% during the forecast period (2015-2025).

The global contrast media injectors market was valued at US$ 979.5 Mn and accounted for 3.0% share of the global diagnostics imaging devices market in 2014. Revenue contribution of contrast media injectors market to the global diagnostics imaging devices market is expected to increase to US$ 1,773.4 Mn by the end of 2025, expanding at a CAGR of 5.6% in terms of value during the forecast period. Continuous adoption of contrast media injectors for contrast media insertion owing to benefits on offer such as increased patient safety, reduced contrast media wastage and increasing demand for early diagnosis of chronic diseases are expected to positively affect growth of the contrast media injectors market across the globe. Global contrast media injectors market has been estimated to be valued at US$ 1,029.2 Mn in 2015, mainly driven by increasing adoption of contrast media injectors in the field of oncology and cardiology.

A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-823 

The report analyses the global contrast media injectors market in terms of market value (US$ Mn) and market volume (units) by product, region and end user, and provides information regarding market dynamics, competitive landscape, current trends, market estimation and forecast.

Adoption rate of contrast media injectors amongst physicians has increased significantly, owing to technological advancements and benefits such as superior prognosis of medical condition due to enhanced quality of images obtained post contrast media insertion. Emergence of alternative techniques for diagnosis of disease such as cancer and side effects caused due to contrast media are certain factors that are expected to hamper growth of the global contrast media injectors market to a certain extent. Major trends in the contrast media injectors market include increased adoption of syringeless contrast media injectors for reduction of contrast media wastage, introduction of advanced software to make the device more user friendly and consistent investment in research and development.

North America dominated the contrast media injectors market with over 33.5% share in terms of value in 2014, and is expected to remain dominant throughout the forecast period. The contrast media injectors market in APEJ and Japan are expected to register robust CAGRs of 5.7% and 5.8% respectively, in terms of value, during the forecast period. Western Europe and Eastern Europe are expected to lose revenue share over the forecast period, as contrast media injectors market is relatively mature in these regions due to increasing adoption of alternative techniques for diagnosis of chronic diseases.

On the basis of product type, contrast media injectors market is segmented into CT injectors, MRI injectors and cardiology injectors. In terms of volume growth, CT injectors segment is expected to account for the maximum share in the market. MRI injectors segment is expected to register highest CAGR over the forecast period, in terms of volume. CT injectors segment is expected to dominate the global contrast media injectors market, in terms of revenue, owing to increasing adoption of combination systems. In terms of volume and value, cardiology injectors segment is expected to register lowest CAGR over the forecast period.

On the basis of end user, contrast media injectors market is segmented into hospitals, ambulatory surgical centres and diagnostics centres. In terms of value and volume, diagnostics centres segment is expected to register lowest CAGR during the forecast period. Hospitals segment revenue growth is majorly driven by increasing installations of imaging modalities in hospitals. Increasing adoption of contrast media injectors among physicians for early diagnosis of chronic disease, especially in the field of oncology and cardiology is fueling revenue growth of the contrast media injectors market.

To view TOC of this report is available upon request @ https://www.futuremarketinsights.com/askus/rep-gb-823

Some of the key market participants included in the report are Mallinckrodt, Guerbet SA, Bayer AG, Bracco Imaging S.p.A., Ulrich GmbH & Co. KG., Medtron AG and Nemoto Kyorindo Co. Ltd.

Increasing out-of-pocket healthcare expenditure and patent expiries of blockbuster drugs fuelling the global branded generics market

A recent research conducted by Future Market Insights predicts that the global market for branded generics will witness a steady growth in terms of revenues. Over a ten-year forecast period from 2016 to 2026, the size of global branded generics market has been estimated to expand at a steady CAGR of 7.3%. Brand-name prescriptions will continue to be ubiquitous among aged people in the world, and since geriatric demographics account for a large portion of global drug-consuming population, demand for branded generics will also rise substantially. In 2016, the global branded generics market has been valued at nearly US$ 200 billion, and is projected to reach US$ 413.8 Bn market valueby the end of forecast period.

A sample of this report is available upon request @  https://www.futuremarketinsights.com/reports/sample/rep-gb-1260

Some of the leading manufacturers of branded generics are based in Asian countries, and are extending their production capacity to keep up with the surging global depend. In Asia-Pacific excluding Japan (APEJ) region, about US$ 150 billion revenues are expected to be procured by the end of 2026. During the forecast period, branded generics market in the APEJ region will attain fastest growth, registering a 10% CAGR, contributing over 35% of global branded generics revenues. North America, Eastern Europe and Latin America are also expected to be lucrative for growth of branded generics sales, while revenues in Western Europe, Japan and Middle East & Africa (MEA) are likely to incur a considerable dip by 2026-end.

Competitive Timeline in Global Branded Generics Market

• Since 2015, Abbott Laboratories, a leading drugmaker in the global pharmaceuticals industry, has aimed at capitalizing from branded generics businesses in developing regions.
• Teva Pharmaceuticals acquired Allergan’s branded generics vertical, while Pfizer Inc. bought Hospira Inc. – both acquisitions have been strategically carried out for repositioning market standings of Teva and Pfizer respectively.
• In December 2016, India-based Sun Pharmaceuticals Industries Ltd. agreed to buy Swiss drugmaker Novartis AG’s branded generics portfolio on cancer medications.
• Another leading branded generics manufacturer, Mylan N.V. recently launched anti-allergy devices which are expected to be half the price of its branded EpiPens.
• Other prominent companies partaking in the growth of global branded generics market include, Aspen Pharmacare Holding Ltd. and Valeant Pharmaceuticals International, Inc.

To view TOC of this report is available upon request @ https://www.futuremarketinsights.com/askus/rep-gb-1260

Research Highlights on Global Branded Generics Market

The report includes a segmental analysis of the global branded generics market, fragmenting its growth on the type of drug formulation, major drug classes, therapeutic applications, and distribution channels. Based on such segmentation, some of the key findings compiled in the report are:

• Nearly three-fifth of the global branded generics revenues estimated in 2016 are expected to be accounted by oral-type formulations, with parenteral, topic and other formulation types collectively accounting for 8% market value share.
• Hospital pharmacies & retail pharmacies will remain as the largest distribution channels for branded generics throughout the globe.
• In 2016 and beyond, the demand for branded generics in therapeutic treatment of cardiovascular diseases will be significant, revenues from which are expected to increase at more than 8% CAGR over the forecast period.
• Global revenues of branded generics accounted by anti-hypertensive drug class are predicted to surpass US$ 25 billion by 2026-end.

Bone Growth Stimulators Market will reach at a CAGR of 9.5% from 2015 to 2025

According to the latest market report published by Future Market Insights titled, “Bone Growth Stimulators Market: Global Industry Analysis and Opportunity Assessment, 2015-2025”, the bone growth stimulators market is anticipated to expand at a CAGR of 9.5% during the forecast period.

Bone growth stimulators are used in cases of delay or failure of fracture healing as they enhance the bone healing process without the sensation of electrical shocks or currents or vibrations when worn by the user. An internal bone growth stimulator or invasive bone growth stimulator is implanted on the fusion site of the bone and it delivers small electrical currents. The internal bone growth stimulator is removed from the body after 6-12 months. External bone growth stimulator or non-invasive bone growth stimulators are externally worn portable devices and do not require surgical implantation. An external bone growth stimulator is prescribed for use for two to nine hours every day for a period of around three to nine months.

A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-828

Economic factors such as improvement in service sector, increase in personal income, and increase in per capita healthcare expenditure are expected to drive market growth globally. Captivating product features, expanding application in the sports medicine industry, high disability cost payments, among others, are fuelling growth of the global bone growth stimulators market. However, various factors such as availability of alternative therapies, uncertainty about efficacy, device-related issues and competition from bone grafts restraint growth of the bone growth stimulators market.

By product, the global bone growth stimulators market is segmented into invasive bone growth stimulators, non-invasive bone growth stimulators and ultrasound bone growth stimulators. The non-invasive bone growth stimulators product segment-which comprises capacitive coupling devices, combined magnetic field devices and pulsed ultrasound magnetic field devices-accounts for the highest market share currently and is expected to remain the leading segment in terms of value during the forecast period. In terms of application segmentation, trauma injury and fractures segment is expected to expand at the highest CAGR in terms of value and volume over the forecast period as compared to other applications. Hospitals end user segment, though projected to account for the highest share in market, is expected to expand at an average CAGR in terms of value and volume over the forecast period. Orthopedic clinics and home care end user segments are expected to represent significant market attractiveness indices over the forecast period.

By region, North America is expected to remain the market leader in the bone growth stimulators market mainly due to consumer awareness about chronic pain related to bone fracture and injury and subsequent disability costs. Western Europe is the second-largest contributor to the global market in terms of value and volume owing to availability of public health systems and subsidies coupled with reliance of patients on the Internet to research about new technologies, such as bone growth stimulators. MEA is projected to expand at a significant pace mainly due to large (particularly expatriate) population, improvements in life expectancy and decline in mortality rates, combined with increased budgetary spend on healthcare, resulting in a major shift and boost in growth of the bone growth stimulators market in the MEA countries. The MEA bone growth stimulators market is still untapped, so companies have substantial growth opportunities in this region.

To view TOC of this report is available upon request @ https://www.futuremarketinsights.com/askus/rep-gb-828

Key market players covered in this report are DJO LLC, Orthofix International N.V., Zimmer Biomet Holdings Inc., Elizur, Bioventus LLC., Ossatec Benelux BV, Verve Consulting Inc. and IGEA S.p.A. Major players in the bone growth stimulators market are focusing on enhancing their global and regional presence through strategic mergers & acquisitions and operational expansion.

Urinary Tract Infection Treatment Market to Grow at a CAGR of 2.1% through 2026

Over 60% physicians are likely to prescribe penicillin and combinations to treat urinary tract infections (UTIs), whereas a vast majority prescribe quinolones in their daily practice to treat complicated cases. A significant percentage of physicians also agreed that they prescribed nitrofurans to treat uncomplicated urinary tract infections in female patients. FMI’s survey also found that cephalosporin is the second-most common drug in the treatment of recurrent and complicated urinary tract infections. 

Prevalence of urinary tract infections is higher in females as compared to males, with biologic and behavioural factors accounting for the major causes. Development of this ailment due to genetic causes or urogenital surgery and Estrogen deficiency was minimal.

A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1340  

FMI’s survey also found that prevalence of uncomplicated URI was significantly higher than complicated-, recurring complicated UTIs. However, prevalence of complicated UTI is expected to increase in the future, owing to increase in drug-resistant bacteria and excessive use of antibiotics.

The global urinary tract infection treatment market is expected to reach US$ 9.42 Bn in revenues. Complex regulatory requirements and low investment in research and development are some of the key factors for sluggish growth of the market. Clinical trials for designing antibacterial drugs are quite complex, owing to which a number of major companies have decreased their R&D spending on the development of new drugs. Moreover, UTI are not chronic like blood pressure or heart diseases and patients are symptom-free usually within 1-2 weeks of treatment, resulting into limited sales of the drugs. In addition to these factors, economic and regulatory hurdles are also restraining the growth of the urinary tract infection treatment market.

By drug type, quinolones account for the highest revenue share of the global urinary tract infection treatment market. This segment is expected to account for nearly 37.2% share of the global urinary tract infection treatment market revenues in 2016. This represents a market value of nearly US$ 3.5 Bn, up from US$ 3.43 Bn in 2015. Among quinolones, levofloxacin is the most sought-after drug type, representing nearly US$ 1.59 Bn in revenues in 2015. Penicillin and combinations is the second largest drug type, and is expected to total US$ 1.87 Bn in revenues.

Retail pharmacies will continue to remain the largest segment in terms of distribution channel in 2016. This segment accounts for nearly 56.8% revenue share, representing a market value of US$ 5.35 Bn. Gynaecology and urology clinics collectively is the second largest segment by distribution channel.

By disease indication, uncomplicated UTI will continue to dominate global revenues. This segment currently accounts for a revenue share of 52.7%, representing a market value of US$ 4.96 Bn in 2016. Neurogenic bladder infections, the second-largest segment by disease indication, is expected to increase by 2.30% in 2016.

Asia Pacific excluding Japan (APEJ) will continue to be the leading market for urinary tract infections, with total revenues expected to reach US$ 3.46 Bn in 2016. Western Europe and North America will remain the second and third largest markets respectively.

Key players operating in the urinary tract infection treatment market include Johnson & Johnson, Boehringer Ingelheim, Cipla Ltd., Bayer AG, GSK, Roche Ltd., Pfizer Inc., Novartis AG, and AstraZeneca plc. The key strategy of a majority of these key players is to expand in emerging markets and achieving inorganic growth through mergers and acquisitions.

To view TOC of this report is available upon request @ https://www.futuremarketinsights.com/askus/rep-gb-1340

Long-term Outlook: The global urinary tract infection treatment market is anticipated to increase at a CAGR of 2.1% during the forecast period 2016-2026 and reach US$ 11.58 Bn in revenues.

Ophthalmic Diagnostic Equipment Market Estimated to Exhibit 5.4% CAGR through 2025

According to the latest market report published by Future Market Insights, titled “Ophthalmic Diagnostic Equipment Market: Global Industry Analysis and Opportunity Assessment 2015-2025”, the ophthalmic diagnostic equipment market is expected to be valued at US$ 2,168.0 Mn by the end of 2015. It is anticipated to expand at a CAGR of 5.4% during the forecast period (2015-2025) to account for US$ 3,656.0 Mn by 2025.

Ophthalmic devices are medical devices used to identify ocular defects or deficiencies and treat eye disorders. As a result of the constant developments in ophthalmic technology for effective treatment of eye diseases and restoration of vision, more and more number of people are opting for ophthalmic surgeries to rectify their eye-related disorders. As per the World Health Organization (WHO) 2010 estimates, there were 285 Mn visually impaired people across the globe in 2010, which included 39 Mn blind people, of whom around 80% were above the age of 50 years. Ophthalmology is the branch of medical science that deals with anatomy, physiology, and disease of the eye. There are various diagnostic equipment that are used to diagnose a wide range of ophthalmic conditions and provide vision solution. These equipment are simple to use for healthcare professionals.

A sample of this report is available upon request @  https://www.futuremarketinsights.com/reports/sample/rep-gb-771

Increasing prevalence of eye-related disorders such as macular degeneration and diabetic retinopathy, rise in aging population and increasing government initiatives towards the development of healthcare infrastructure in the developing countries are the key factors driving growth of the global ophthalmic devices market currently. 

In addition, increasing prevalence of lifestyle associated diseases, such as diabetes and high blood pressure, is fuelling growth of the market further. In case of the geriatric population, treatment of eye diseases calls for more effective ophthalmology devices. Several government associations across the globe are also focused on increasing consumer awareness about ophthalmic diseases. However, various factors, such as lack of awareness about eye diseases and high risks associated with eye surgeries, act as restraints for growth of the ophthalmology devices market. Also, there are some problems associated with the use of ophthalmology devices; for instance, changes made to the cornea cannot be reversed after LASIK surgery.

By region, North America dominated the ophthalmic diagnostic equipment market with over 31.1% value share in 2014 and is expected to remain dominant throughout the forecast period. The ophthalmic diagnostic equipment market in Asia and Latin America is expected to expand at a CAGR of 5.9% and 5.7%, respectively, in terms of value, during the forecast period. Meanwhile, the Optical Coherence Tomography (OCT) product segment is expected to account for the maximum value share of the overall market during the forecast period.

Dearth of ophthalmologists and lack of associations capable of understanding the needs of the ophthalmologists are among the major factors restraining growth of the ophthalmic diagnostic equipment market currently. Meanwhile, factors such as launch of advanced technologies, product innovation, new patent approvals and research institutes and universities play a major role in driving the market growth.

To view TOC of this report is available upon request @ https://www.futuremarketinsights.com/askus/rep-gb-771

Key market players covered in this report are TOPCON CORPORATION, Carl Zeiss Vision International GmbH, Ellex, Quantel Medical Inc, NIDEK CO., LTD, HAAG-STREIT GROUP, Halma plc, Coburn Technologies Inc. and Kowa Company Ltd. Major players in the ophthalmic diagnostic equipment market focus on enhancing their global and regional presence through strategic acquisitions and mergers, and operational expansion.